18. Tác dụng phụ của điều trị duy trì bằng capecitabine có hoặc không phối hợp Bevacizumab ở bệnh nhân ung thư đại trực tràng di căn

Abstract

The primary goal in the treatment of metastatic colorectal cancer (mCRC) is to prolong survival while minimizing treatment-related toxicities. This study aimed to evaluate the adverse events associated with maintenance therapy using capecitabine with or without bevacizumab in patients with mCRC. A descriptive cross-sectional study with longitudinal follow-up was conducted on 148 patients. The most common treatment-related adverse events of any grade were hand-foot syndrome (33.1%), diarrhea (16.9%), and hypertension (13.5%). Notably, the incidence of hypertension was significantly higher in the capecitabine + bevacizumab group compared to the capecitabine monotherapy group (28.1% vs. 5.6%, p = 0.044). Grade 3 - 4 hypertension was the most frequently observed severe adverse event in the combination therapy group (6.4% vs. 1.9%). Age ≥ 65 years was identified as an independent risk factor for grade 3 - 4 toxicity, with an odds ratio (OR) of 4.006 (95% CI: 1.624–9.878, p = 0.003).